TITLE

Clinic Roundup

PUB. DATE
March 2013
SOURCE
BioWorld Today;3/27/2013, Vol. 24 Issue 58, p5
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
This section offers news briefs on the pharmaceuticals and biotechnology sector. BioCryst Pharmaceuticals Inc. of Research Triangle Park, North Carolina announced that is has begun a Phase I trial in healthy volunteers to evaluate orally administered BCX4161, a selective inhibitor of plasma kallikrein that aims to prevent attacks in patients with hereditary angioedema. Catabasis Pharmaceuticals Inc. has started a Phase I study to test CAT-2003.
ACCESSION #
86442014

 

Related Articles

  • Clinic Roundup.  // BioWorld Today;7/25/2012, Vol. 23 Issue 143, p10 

    This section offers news briefs on the pharmaceutical industry. Results of a Phase III trial involving Amarin Corp. plc's AMR101 are available electronically through "The American Journal of Cardiology." BioCryst Pharmaceuticals Inc. has released Phase IIb trial results showing the safety and...

  • Dyax Angioedema Drug Meets Phase III Goal.  // Bioworld Week;8/25/2008, Vol. 16 Issue 34, p3 

    The article reports on the result of the second Phase III trial of Dyax Corp.'s experimental drug DX-88 (ecallantide) as a treatment for hereditary angioedema (HAE). The result reveals that the drug was able to accomplish its goal of reducing symptoms of HAE. It further states that Dyax is...

  • BioCryst's Fodosine: Following The Lead Of Zolinza Approval? Osborne, Randall // BioWorld Financial Watch;4/2/2007, Vol. 15 Issue 14, p1 

    The article discusses the implications of new clinical trial regulations implemented by the U.S. Food and Drug Administration (FDA) for the development of intravenous Fodosine developed by BioCryst Pharmaceuticals Inc. The FDA has prohibited special protocol assessment (SPA) to randomized trials...

  • BioCryst Stock Takes a Hit as Peramivir Trial Extended. Shaffer, Catherine // BioWorld Today;1/14/2011, Vol. 22 Issue 10, p1 

    The article reports on the 6.7 percent decrease in the stock of BioCryst Pharmaceuticals Inc. after the company announced that it will extend the enrollment period for the clinical trial of its peramivir drug for hospitalized influenza patients. Such extension is a result of the changes in the...

  • CLINIC ROUNDUP.  // BioWorld Today;2/24/2009, Vol. 20 Issue 35, p13 

    This section offers news briefs on clinical trials. BioCryst Pharmaceuticals Inc. announced the full dataset from an exploratory Phase II study of peramivir, a neuraminidase inhibitor, in patients with influenza. BN ImmunoTherapeutics Inc. revealed that a study of breast cancer vaccine...

  • BioCryst suspends trial of leukemia treatment.  // PharmaWatch: Biotechnology;May2007, Vol. 6 Issue 5, p6 

    The article provides updates on the phase IIb trial of BioCryst Pharmaceuticals Inc. of its intravenous Fodosine for leukemia patients. The trial was suspended due to a stability issue with the formulation of the drug. Preliminary findings suggested that the particulate matter in the intravenous...

  • BioCryst's Peramivir as Good as Tamiflu.  // Bioworld Week;7/27/2009, Vol. 17 Issue 30, p2 

    The article reports on the result of the Phase III study of the seasonal flu drug peramivir from BioCryst Pharmaceuticals Inc., which proved noninferior to Tamiflu. It notes that the result has encouraged investors for a government stockpiling contract to deal with the invasive threat of swine...

  • Pharma: Clinic Roundup.  // BioWorld Today;10/29/2013, Vol. 24 Issue 208, p12 

    This section offers news briefs pertaining to clinical trials of drugs as of October 29, 2013, including Boehringer Ingelheim GmbH's Phase II and Phase III studies that tested tiotropium in asthma, and the presentation of results from lung cancer cohort of the study of Bristol-Myers Squibb Co.'s...

  • Pharma: Other News To Note.  // BioWorld Today;10/29/2013, Vol. 24 Issue 208, p12 

    This section offers news briefs pertaining to the pharmaceutical industry as of October 29, 2013, including the filing of an abbreviated new drug application for Clindamycin Phosphate and Benzoyl Peroxide Gel by Activis PLC, the signing of an agreement by Cumberland Pharmaceuticals Inc. and...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics